Literature DB >> 26529178

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

Armin Rashidi1, Maryam Ebadi2, Graham A Colditz3, John F DiPersio4.   

Abstract

A large number of elderly patients with acute myeloid leukemia (AML) are not offered treatments with curative intent, such as allogeneic stem cell transplantation (SCT), because of fears of toxicity and perceived futility of intensive treatment. Therefore, the outcomes of SCT in elderly AML patients remain poorly defined. We performed a meta-analysis of all previous articles up until September 22, 2015 of SCT in AML patients >60 years. The primary endpoints were relapse-free survival (RFS) and overall survival (OS) at 6 months and at 1, 2, and 3 years. A total of 13 studies (749 patients) were included. The pooled estimates and 95% confidence intervals (CI) for RFS at 6 months, 1 year, 2 years, and 3 years were 62% (95% CI, 54% to 69%), 47% (95% CI, 42% to 53%), 44% (95% CI, 33% to 55%), and 35% (95% CI, 26% to 45%), respectively. The corresponding numbers for OS were 73% (95% CI, 66% to 79%), 58% (95% CI, 50% to 65%), 45% (95% CI, 35% to 54%), and 38% (95% CI, 29% to 48%), respectively. We found no evidence of publication bias in our primary endpoints, with the exception of relapse, where there appeared to be a relative lack of small studies with high relapse rates. Sensitivity analysis did not identify an overtly influential study for our primary endpoints, with 1 exception in 2-year RFS analysis. The present analysis argues against significant publication bias and demonstrates consistency among reports despite differences in patient-, disease-, center-, and transplantation-related characteristics. Our results suggest that reduced-intensity SCT is a viable treatment option for elderly AML patients with a 3-year RFS of 35% for those over the age of 60. These results argue against using age per se as the sole criterion against SCT and would help remove some of the barriers that often preclude curative intent treatment. Correct identification of patients who would benefit from SCT can improve outcomes in this frequently undertreated population.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic; Elderly; Leukemia; Outcome; Reduced-intensity; Transplantation

Mesh:

Substances:

Year:  2015        PMID: 26529178      PMCID: PMC4805505          DOI: 10.1016/j.bbmt.2015.10.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  33 in total

1.  Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.

Authors:  Vikas Gupta; Andrew Daly; Jeffrey H Lipton; Wanda Hasegawa; Kathy Chun; Suzanne Kamel-Reid; Richard Tsang; Qi-long Yi; Mark Minden; Hans Messner; Thomas Kiss
Journal:  Biol Blood Marrow Transplant       Date:  2005-10       Impact factor: 5.742

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.

Authors:  Kathryn Jackson; Glen Kennedy; Peter Mollee; Paula Marlton; Kirk Morris
Journal:  Asia Pac J Clin Oncol       Date:  2014-03-27       Impact factor: 2.601

4.  Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.

Authors:  Herschel Wallen; Theodore A Gooley; H Joachim Deeg; John M Pagel; Oliver W Press; Frederick R Appelbaum; Rainer Storb; Ajay K Gopal
Journal:  J Clin Oncol       Date:  2005-04-11       Impact factor: 44.544

5.  Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.

Authors:  Hartmut Bertz; Karin Potthoff; Jürgen Finke
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

6.  Allogeneic hematopoietic cell transplantation may alleviate the negative prognostic impact of monosomal and complex karyotypes on patients with acute myeloid leukemia.

Authors:  Robert J Guo; Eshetu G Atenafu; Ken Craddock; Hong Chang
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-31       Impact factor: 5.742

7.  Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.

Authors:  Fotios V Michelis; Hans A Messner; Eshetu G Atenafu; Dennis D Kim; John Kuruvilla; Jeffrey H Lipton; Jieun Uhm; David Loach; Vikas Gupta
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-15       Impact factor: 5.742

8.  Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Authors:  Yvette L Kasamon; Javier Bolaños-Meade; Gabrielle T Prince; Hua-Ling Tsai; Shannon R McCurdy; Jennifer A Kanakry; Gary L Rosner; Robert A Brodsky; Karlo Perica; B Douglas Smith; Douglas E Gladstone; Lode J Swinnen; Margaret M Showel; William H Matsui; Carol Ann Huff; Ivan Borrello; Keith W Pratz; Michael A McDevitt; Ivana Gojo; Amy E Dezern; Satish Shanbhag; Mark J Levis; Leo Luznik; Richard F Ambinder; Ephraim J Fuchs; Richard J Jones
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

9.  Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.

Authors:  Steven M Devine; Kouros Owzar; William Blum; Flora Mulkey; Richard M Stone; Jack W Hsu; Richard E Champlin; Yi-Bin Chen; Ravi Vij; James Slack; Robert J Soiffer; Richard A Larson; Thomas C Shea; Vera Hars; Alexander B Sibley; Sergio Giralt; Shelly Carter; Mary M Horowitz; Charles Linker; Edwin P Alyea
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

Review 10.  To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.

Authors:  C Ustun; H M Lazarus; D Weisdorf
Journal:  Bone Marrow Transplant       Date:  2013-05-06       Impact factor: 5.483

View more
  26 in total

1.  Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia.

Authors:  Antonio Pierini; Loredana Ruggeri; Alessandra Carotti; Franca Falzetti; Simonetta Saldi; Adelmo Terenzi; Claudio Zucchetti; Gianluca Ingrosso; Tiziana Zei; Roberta Iacucci Ostini; Sara Piccinelli; Samanta Bonato; Sara Tricarico; Antonella Mancusi; Sara Ciardelli; Roberto Limongello; Mara Merluzzi; Mauro Di Ianni; Rita Tognellini; Olivia Minelli; Cristina Mecucci; Maria Paola Martelli; Brunangelo Falini; Massimo Fabrizio Martelli; Cynthia Aristei; Andrea Velardi
Journal:  Blood Adv       Date:  2021-03-09

2.  Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Authors:  Stefan O Ciurea; Mithun V Shah; Rima M Saliba; Sameh Gaballa; Piyanuch Kongtim; Gabriela Rondon; Julianne Chen; Whitney Wallis; Kai Cao; Marina Konopleva; Naval Daver; Jorge Cortes; Farhad Ravandi; Amin Alousi; Sairah Ahmed; Uday Popat; Simrit Parmar; Qaiser Bashir; Oran Betul; Chitra Hosing; Elizabeth J Shpall; Katayoun Rezvani; Issa F Khouri; Partow Kebriaei; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-14       Impact factor: 5.742

Review 3.  Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Lacey Williams; Kimberley Doucette; Judith E Karp; Catherine Lai
Journal:  Bone Marrow Transplant       Date:  2021-03-08       Impact factor: 5.483

Review 4.  Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.

Authors:  Zhi-Hui Zhang; Xin-Yue Lian; Dong-Ming Yao; Pin-Fang He; Ji-Chun Ma; Zi-Jun Xu; Hong Guo; Wei Zhang; Jiang Lin; Jun Qian
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-03       Impact factor: 4.553

Review 5.  Aging: Treating the Older Patient.

Authors:  Ashley Rosko; Andrew Artz
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-15       Impact factor: 5.742

6.  Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.

Authors:  D Modi; A Deol; S Kim; L Ayash; A Alavi; M Ventimiglia; D Bhutani; V Ratanatharathorn; J P Uberti
Journal:  Bone Marrow Transplant       Date:  2017-09-04       Impact factor: 5.483

7.  Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.

Authors:  Masamichi Isobe; Takaaki Konuma; Masayoshi Masuko; Naoyuki Uchida; Shigesaburo Miyakoshi; Yasuhiro Sugio; Shuro Yoshida; Masatsugu Tanaka; Yoshiko Matsuhashi; Norimichi Hattori; Makoto Onizuka; Nobuyuki Aotsuka; Yasushi Kouzai; Atsushi Wake; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Journal:  Ann Hematol       Date:  2021-02-23       Impact factor: 3.673

8.  Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.

Authors:  Richard J Lin; Patrick D Hilden; Theresa A Elko; Parastoo B Dahi; Armin Shahrokni; Ann A Jakubowski; Miguel-Angel Perales; Craig S Sauter; Hugo R Castro-Malaspina; Juliet N Barker; Brian C Shaffer; Roni Tamari; Esperanza B Papadopoulos; Molly A Maloy; Beatriz Korc-Grodzicki; Sergio A Giralt
Journal:  Blood Adv       Date:  2019-01-08

9.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Authors:  Mikkael A Sekeres; Gordon Guyatt; Gregory Abel; Shabbir Alibhai; Jessica K Altman; Rena Buckstein; Hannah Choe; Pinkal Desai; Harry Erba; Christopher S Hourigan; Thomas W LeBlanc; Mark Litzow; Janet MacEachern; Laura C Michaelis; Sudipto Mukherjee; Kristen O'Dwyer; Ashley Rosko; Richard Stone; Arnav Agarwal; L E Colunga-Lozano; Yaping Chang; QiuKui Hao; Romina Brignardello-Petersen
Journal:  Blood Adv       Date:  2020-08-11

10.  The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients.

Authors:  Richard J Lin; Laure Michaud; Stephanie M Lobaugh; Reiko Nakajima; Audrey Mauguen; Theresa A Elko; Josel D Ruiz; Molly A Maloy; Craig S Sauter; Parastoo B Dahi; Miguel-Angel Perales; Gunjan L Shah; Nerea Castillo Flores; Míriam Sanchez-Escamilla; Ana Alarcón Tomas; Lucrecia Yáñez San Segundo; Christina Cho; Ioannis Politikos; Soo Jung Kim; Beatriz Korc-Grodzicki; Sean M Devlin; Michael Scordo; Heiko Schöder; Sergio A Giralt; Paul A Hamlin
Journal:  Leuk Lymphoma       Date:  2020-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.